New analysis from Clarivate Analytics' Cortellis Forecast Team predicts 11 medicines set to enter the market in 2020 will reach more than $1 billion in sales by 2024. Drugs for central nervous system indications and cancer dominate the list, almost universally accelerated in their development by orphan drug status or other designation intended to speed their path to market. Most medicines are for indications in markets already crowded with competitors, meaning they'll face substantial pressures to differentiate from existing products.
Editors and writers examine the various disease landscapes from all angles, check the pricing strategies, explore the science underpinning the new medicines and provide reality checks via the ultimate test: patients who will use the drugs.
The articles in this collection are freely available.
CNS: Ofatumumab, ozanimod, rimegepant
Hematologic: Vadadustat, Valrox
Metabolic: Inclisiran, Rybelsus
Oncology: Enhertu, liso-cel, sacituzumab govitecan